FDA grants accelerated approval to tazemetostat for follicular lymphoma
The Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for…
Browsing: tazemetostat
FDA approves first treatment option specifically for patients with epithelioid sarcoma, a rare soft tissue cancer
The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat for the treatment…
Targeted therapy that can help children with deadly nerve cancer
Mount Sinai researchers have identified a targeted therapy for adolescent patients with neuroblastoma, a deadly…